CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF529 (ImmuneEditome ID:57711)

1. Gene summary of enriched editing regions for ZNF529

check button Gene summary
Gene informationGene symbol

ZNF529

Gene ID

57711

GeneSynonyms-
GeneCytomap

19q13.12

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 529
GeneModificationdate20230518
UniprotIDQ6P280;K7EKM0;K7ESA1;A0A0C4DFR4;K7ES80;K7ELR0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:36545928-36546329:-ENST00000590656.1ENSG00000186020.11ZNF529exonic(GT)n,(AT)nchr19:36545928-36546329:-.alignment


Top

2. Tumor-specific enriched editing regions for ZNF529


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:36545928-36546329:-BRCAEER2.5864e-03image
ENSG00000186020.11,ZNF529BRCAEAG2.0926e-02image
chr19:36545928-36546329:-THCAEER1.7344e-06image
ENSG00000186020.11,ZNF529THCAEAG1.0767e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:36545928-36546329:-KIRCPathEER5.8196e-041.2867e-040.2158image
ENSG00000186020.11,ZNF529KIRCPathEAG1.4994e-034.8099e-040.1941image
chr19:36545928-36546329:-THCAPathEER7.9051e-035.9226e-040.2044image
ENSG00000186020.11,ZNF529THCAPathEAG3.7345e-027.1604e-030.1568image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000186020.11,ZNF529LIHCEAG3.0120e-027.1601e-035.5017e+02image

Top

3. Enriched editing regions and immune related genes for ZNF529


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:36545928-36546329:-ESCAEERENSG00000152443,ZNF776-0.50092.7087e-052.6836e-07-0.4329imageNAIFM1;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RANGAP1;RBM10;SMNDC1;SRSF1;SRSF9;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:36545928-36546329:-ESCAEERENSG00000172888,ZNF621-0.49922.7973e-051.4307e-06-0.4082imageNAIFM1;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPK;IGF2BP2;LIN28B;NONO;RANGAP1;RBM10;SLBP;SMNDC1;SRSF1;SRSF9;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:36545928-36546329:-ESCAEERENSG00000196417,ZNF765-0.47867.8635e-057.8891e-07-0.4172imageNDDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RBM10;SMNDC1;SRSF1;SRSF9NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:36545928-36546329:-ESCAEERENSG00000128000,ZNF780B-0.48198.1231e-055.5072e-07-0.4225imageNAIFM1;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RANGAP1;RBM10;SMNDC1;SRSF1;SRSF9;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:36545928-36546329:-ESCAEERENSG00000198482,ZNF808-0.46951.2875e-041.1494e-06-0.4115imageNDDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RBM10;SLBP;SRSF1;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:36545928-36546329:-ESCAEERENSG00000254004,ZNF260-0.46661.8201e-041.4067e-07-0.4420imageNDDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;RANGAP1;RBM10;SLBP;SRSF1;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:36545928-36546329:-ESCAEERENSG00000188283,ZNF383-0.46092.3571e-041.9029e-06-0.4038imageNDDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RANGAP1;RBM10;SMNDC1;SRSF1;SRSF9;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_GLYCOLYSIS
chr19:36545928-36546329:-ESCAEERENSG00000122482,ZNF644-0.45552.9393e-045.5324e-07-0.4225imageNAIFM1;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RANGAP1;RBM10;SLBP;SMNDC1;SRSF1;SRSF9;YTHDC1NAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:36545928-36546329:-ESCAEERENSG00000186376,ZNF75D-0.44743.3583e-042.2483e-06-0.4011imageNAIFM1;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RANGAP1;RBM10;SMNDC1;SRSF1;SRSF9;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
chr19:36545928-36546329:-ESCAEERENSG00000186020,ZNF529-0.45203.7310e-042.7567e-07-0.4326imageNAIFM1;ALKBH5;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RANGAP1;RBM10;SLBP;SMNDC1;SRSF1;SRSF9;YTHDC1NANeutrophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

4. Enriched editing regions and immune related splicing for ZNF529


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000186020.11,ZNF529
ESCAEAGIRENSG00000184990.8chr14104756574:104756760:104759218:104759653-0.35091.3972e-022.3622e-06-0.4478imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZC3H7B;ZNF184SIVA1Dendritic_cells_activatedGSVA_HALLMARK_MTORC1_SIGNALING
chr19:36545928-36546329:-
ESCAEERIRENSG00000088832.10chr201368977:1370072:1371021:1371147-0.34303.4568e-021.5123e-06-0.4211imageNAIFM1;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;RANGAP1;RBM10;SLBP;SMNDC1;SRSF1;SRSF9;YTHDC1FKBP1AMacrophages_M0GSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000186020.11,ZNF529
ESCAEAGIRENSG00000088832.10chr201368977:1370072:1371021:1371147-0.35462.6897e-026.4169e-07-0.4311imageNADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;RTCB;SAFB2;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184FKBP1AMacrophages_M0GSVA_HALLMARK_MTORC1_SIGNALING
chr19:36545928-36546329:-
ESCAEERIRENSG00000073169.9chr2250200978:50201590:50206320:50206440-0.29934.3969e-021.6097e-05-0.4056imageNAIFM1;ALKBH5;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RANGAP1;RBM10;SMNDC1;SRSF1;SRSF9;YTHDC1NAT_cells_CD4_memory_restingGSVA_HALLMARK_HYPOXIA
ENSG00000186020.11,ZNF529
ESCAEAGIRENSG00000162613.12chr177948404:77948914:77949154:77949267-0.44381.7953e-031.0027e-07-0.4435imageNACIN1;ADAR;AIFM1;ALKBH5;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;RTCB;SAFB2;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAMast_cells_restingGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000186020.11,ZNF529
ESCAEAGIRENSG00000060138.8chr1210702395:10702512:10704050:10704148-0.30104.1143e-026.1773e-06-0.4452imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MYC_TARGETS_V1
chr19:36545928-36546329:-
ESCAEERIRENSG00000049656.9chr51324762:1325816:1326014:1326027-0.30313.6998e-027.8225e-06-0.4495imageNAIFM1;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RANGAP1;RBM10;SLBP;SMNDC1;SRSF1;SRSF9;YTHDC1CLPTM1LT_cells_CD4_memory_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:36545928-36546329:-
ESCAEERIRENSG00000184083.7chrX54173788:54174146:54182499:54182778-0.33231.7962e-021.6066e-05-0.4207imageNAIFM1;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;RANGAP1;RBM10;SRSF1;SRSF9;YTHDC1NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000186020.11,ZNF529
ESCAEAGIRENSG00000240344.4chr2200884901:200885367:200885697:200885772-0.30404.2694e-027.6351e-05-0.4005imageNACIN1;ADAR;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184PPIL3Macrophages_M2GSVA_HALLMARK_UV_RESPONSE_UP
chr19:36545928-36546329:-
ESCAEERIRENSG00000162613.12chr177948404:77948914:77949154:77949267-0.43492.5770e-032.1367e-07-0.4362imageNAIFM1;ALKBH5;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;HNRNPK;IGF2BP2;LIN28B;NONO;RANGAP1;RBM10;SLBP;SMNDC1;SRSF1;SRSF9;YTHDC1NAMast_cells_restingGSVA_HALLMARK_MTORC1_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for ZNF529


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:36545928-36546329:-BRCAEERT_cells_regulatory_(Tregs)5.7267e-050.1640image
ENSG00000186020.11,ZNF529BRCAEAGT_cells_regulatory_(Tregs)1.6206e-030.1248image
ENSG00000186020.11,ZNF529COADEAGB_cells_memory9.7968e-040.4323image
chr19:36545928-36546329:-ESCAEERMacrophages_M24.5631e-040.3031image
ENSG00000186020.11,ZNF529ESCAEAGMacrophages_M21.9462e-040.3188image
chr19:36545928-36546329:-GBMEERMacrophages_M02.1211e-02-0.2426image
ENSG00000186020.11,ZNF529GBMEAGMonocytes2.6626e-020.2312image
ENSG00000186020.11,ZNF529HNSCEAGT_cells_CD4_memory_resting4.1438e-020.2734image
chr19:36545928-36546329:-KIRCEERT_cells_CD4_naive2.3524e-020.1527image
ENSG00000186020.11,ZNF529KIRCEAGT_cells_CD4_naive1.6811e-020.1586image
ENSG00000186020.11,ZNF529KIRPEAGMacrophages_M13.5236e-020.3678image
chr19:36545928-36546329:-LAMLEERT_cells_regulatory_(Tregs)5.3647e-030.2806image
ENSG00000186020.11,ZNF529LAMLEAGMonocytes3.6941e-020.2100image
chr19:36545928-36546329:-LGGEERMacrophages_M03.2762e-03-0.1748image
ENSG00000186020.11,ZNF529LGGEAGMacrophages_M06.7506e-03-0.1590image
ENSG00000186020.11,ZNF529LIHCEAGDendritic_cells_resting1.7251e-020.3746image
chr19:36545928-36546329:-LUADEERT_cells_CD4_memory_activated1.5980e-020.1694image
ENSG00000186020.11,ZNF529LUADEAGT_cells_CD4_memory_activated8.7567e-030.1796image
chr19:36545928-36546329:-LUSCEERPlasma_cells1.1879e-020.1717image
ENSG00000186020.11,ZNF529LUSCEAGPlasma_cells1.0347e-020.1722image
ENSG00000186020.11,ZNF529MESOEAGMacrophages_M21.1368e-020.5534image
chr19:36545928-36546329:-OVEEREosinophils1.4996e-070.3193image
ENSG00000186020.11,ZNF529OVEAGEosinophils3.9070e-080.3320image
chr19:36545928-36546329:-PCPGEERT_cells_gamma_delta2.2699e-030.3306image
ENSG00000186020.11,ZNF529PCPGEAGT_cells_gamma_delta6.9367e-030.2812image
ENSG00000186020.11,ZNF529PRADEAGNK_cells_activated1.9201e-030.2420image
chr19:36545928-36546329:-SARCEERT_cells_CD4_memory_activated5.8788e-040.3516image
ENSG00000186020.11,ZNF529SARCEAGT_cells_CD4_memory_activated1.5532e-040.3712image
chr19:36545928-36546329:-SKCMEERT_cells_follicular_helper2.5341e-020.1838image
ENSG00000186020.11,ZNF529SKCMEAGMacrophages_M13.0112e-020.1748image
ENSG00000186020.11,ZNF529STADEAGEosinophils1.0486e-020.1692image
chr19:36545928-36546329:-TGCTEERPlasma_cells4.1938e-020.2371image
ENSG00000186020.11,ZNF529TGCTEAGT_cells_gamma_delta1.7315e-02-0.2655image
chr19:36545928-36546329:-THCAEERDendritic_cells_resting4.9575e-030.1669image
ENSG00000186020.11,ZNF529THCAEAGDendritic_cells_resting4.9714e-030.1631image
ENSG00000186020.11,ZNF529UCSEAGMacrophages_M12.7209e-02-0.4328image


Top

6. Enriched editing regions and immune gene sets for ZNF529


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000186020.11,ZNF529BLCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG5.3304e-030.3106image
ENSG00000186020.11,ZNF529BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG7.4915e-050.1565image
chr19:36545928-36546329:-BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.2053e-080.2241image
chr19:36545928-36546329:-CESCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER4.7795e-030.3484image
ENSG00000186020.11,ZNF529CESCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG2.0323e-030.3731image
ENSG00000186020.11,ZNF529COADGSVA_HALLMARK_E2F_TARGETSEAG2.4150e-030.4010image
ENSG00000186020.11,ZNF529ESCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.1486e-040.3294image
chr19:36545928-36546329:-ESCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.0659e-040.3333image
ENSG00000186020.11,ZNF529GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG5.1581e-030.2893image
chr19:36545928-36546329:-GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER8.0717e-030.2776image
chr19:36545928-36546329:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.1843e-030.2055image
ENSG00000186020.11,ZNF529KIRCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG7.4044e-030.1773image
ENSG00000186020.11,ZNF529KIRPGSVA_HALLMARK_MYC_TARGETS_V2EAG1.8947e-020.4064image
chr19:36545928-36546329:-LAMLGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER5.6504e-030.2790image
ENSG00000186020.11,ZNF529LAMLGSVA_HALLMARK_NOTCH_SIGNALINGEAG7.3322e-030.2679image
chr19:36545928-36546329:-LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.2770e-04-0.2266image
ENSG00000186020.11,ZNF529LGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.0458e-04-0.2067image
ENSG00000186020.11,ZNF529LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.6826e-020.3759image
chr19:36545928-36546329:-LUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.3919e-020.1728image
ENSG00000186020.11,ZNF529LUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG9.0164e-030.1790image
chr19:36545928-36546329:-LUSCGSVA_HALLMARK_APOPTOSISEER2.4014e-060.3160image
ENSG00000186020.11,ZNF529LUSCGSVA_HALLMARK_APOPTOSISEAG2.0849e-060.3129image
ENSG00000186020.11,ZNF529MESOGSVA_HALLMARK_DNA_REPAIREAG1.5967e-030.6584image
chr19:36545928-36546329:-OVGSVA_HALLMARK_MITOTIC_SPINDLEEER4.1637e-06-0.2816image
ENSG00000186020.11,ZNF529OVGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.2265e-05-0.2670image
ENSG00000186020.11,ZNF529PCPGGSVA_HALLMARK_COAGULATIONEAG1.0942e-020.2656image
chr19:36545928-36546329:-PCPGGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.1422e-020.2764image
ENSG00000186020.11,ZNF529PRADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.6499e-020.1882image
ENSG00000186020.11,ZNF529READGSVA_HALLMARK_UV_RESPONSE_UPEAG1.1247e-020.4983image
chr19:36545928-36546329:-SARCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.8363e-040.3567image
ENSG00000186020.11,ZNF529SARCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG3.9527e-03-0.2872image
chr19:36545928-36546329:-SKCMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.1447e-020.2074image
ENSG00000186020.11,ZNF529SKCMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.4494e-020.1967image
ENSG00000186020.11,ZNF529STADGSVA_HALLMARK_MITOTIC_SPINDLEEAG9.0058e-03-0.1726image
ENSG00000186020.11,ZNF529TGCTGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG9.9390e-030.2867image
chr19:36545928-36546329:-TGCTGSVA_HALLMARK_COAGULATIONEER7.1077e-030.3104image
ENSG00000186020.11,ZNF529THCAGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.0867e-030.1893image
chr19:36545928-36546329:-THCAGSVA_HALLMARK_P53_PATHWAYEER2.8834e-050.2463image
chr19:36545928-36546329:-THYMGSVA_HALLMARK_ADIPOGENESISEER1.9188e-020.3688image
ENSG00000186020.11,ZNF529THYMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.2131e-020.3882image
ENSG00000186020.11,ZNF529UCECGSVA_HALLMARK_APOPTOSISEAG6.0101e-030.3726image


Top

7. Enriched editing regions and drugs for ZNF529


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000186020.11,ZNF529BLCAABT.263EAG6.9576e-030.3014image
chr19:36545928-36546329:-BRCABMS.536924EER1.4298e-04-0.1554image
ENSG00000186020.11,ZNF529BRCAAZD.0530EAG4.5921e-03-0.1125image
chr19:36545928-36546329:-CESCErlotinibEER4.4931e-03-0.3507image
ENSG00000186020.11,ZNF529CESCErlotinibEAG3.9690e-03-0.3500image
ENSG00000186020.11,ZNF529COADGW843682XEAG3.7800e-03-0.3842image
ENSG00000186020.11,ZNF529ESCABI.D1870EAG7.4090e-04-0.2901image
chr19:36545928-36546329:-ESCADocetaxelEER8.9482e-04-0.2879image
ENSG00000186020.11,ZNF529GBMCGP.082996EAG1.3567e-02-0.2565image
chr19:36545928-36546329:-GBMLapatinibEER5.5236e-03-0.2902image
ENSG00000186020.11,ZNF529HNSCMetforminEAG7.9677e-03-0.3511image
ENSG00000186020.11,ZNF529KIRCDasatinibEAG3.5253e-03-0.1937image
chr19:36545928-36546329:-KIRCDasatinibEER3.2580e-04-0.2412image
ENSG00000186020.11,ZNF529KIRPCMKEAG2.8643e-02-0.3811image
ENSG00000186020.11,ZNF529LAMLCI.1040EAG1.0140e-02-0.2573image
chr19:36545928-36546329:-LAMLCI.1040EER1.6948e-03-0.3147image
ENSG00000186020.11,ZNF529LGGCisplatinEAG2.2351e-040.2155image
chr19:36545928-36546329:-LGGEmbelinEER2.0580e-040.2197image
ENSG00000186020.11,ZNF529LIHCBosutinibEAG1.0821e-020.3987image
ENSG00000186020.11,ZNF529LUSCCI.1040EAG8.4755e-05-0.2613image
chr19:36545928-36546329:-LUSCCI.1040EER6.2683e-05-0.2701image
ENSG00000186020.11,ZNF529MESOCCT018159EAG9.7641e-03-0.5629image
chr19:36545928-36546329:-OVAZD6482EER3.8030e-080.3341image
ENSG00000186020.11,ZNF529OVAZD6482EAG6.4969e-070.3028image
ENSG00000186020.11,ZNF529PAADErlotinibEAG1.1354e-02-0.3915image
chr19:36545928-36546329:-PCPGJNJ.26854165EER1.8990e-03-0.3360image
ENSG00000186020.11,ZNF529PCPGAZD7762EAG8.4819e-03-0.2744image
ENSG00000186020.11,ZNF529PRADEpothilone.BEAG3.1998e-030.2303image
ENSG00000186020.11,ZNF529READGDC0941EAG4.2902e-030.5512image
chr19:36545928-36546329:-SARCCCT007093EER2.2141e-030.3152image
ENSG00000186020.11,ZNF529SARCAG.014699EAG1.0063e-020.2576image
chr19:36545928-36546329:-SKCMAZD.0530EER1.4413e-030.2596image
ENSG00000186020.11,ZNF529SKCMAZD.0530EAG1.8945e-030.2484image
ENSG00000186020.11,ZNF529STADBAY.61.3606EAG4.9334e-040.2289image
chr19:36545928-36546329:-TGCTCGP.60474EER1.0837e-03-0.3724image
ENSG00000186020.11,ZNF529TGCTAxitinibEAG6.4171e-030.3023image
ENSG00000186020.11,ZNF529THCABIBW2992EAG4.5315e-03-0.1648image
chr19:36545928-36546329:-THCAEmbelinEER1.7771e-050.2525image
chr19:36545928-36546329:-THYMEmbelinEER7.6497e-030.4156image
ENSG00000186020.11,ZNF529THYMEmbelinEAG1.2733e-020.3858image
chr19:36545928-36546329:-UCSBMS.509744EER2.2316e-02-0.4642image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType